Treats migraine with or without aura. ANDA 211292, held by Amneal Pharms Co. Frovatriptan Succinate.
As of Nov 16, 2026, ANDA 211292 (Frovatriptan Succinate), held by Amneal Pharms Co, was first approved by FDA on Nov 6, 2018, with 1 approved supplement and 0 published complete response letters.
Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 6, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Frovatriptan SuccinateEQ 2.5MG BASE · tablet;oral | Frovatriptan Succinate | Rx |
| May 17, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 6, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters